AI Article Synopsis

  • - Trypanosoma brucei is a parasite responsible for human African trypanosomiasis (HAT) and relies on an enzyme called trypanosome alternative oxidase (TAO) for respiration.
  • - A new drug candidate, Ascofuranone (AF), targets TAO specifically, making it a promising option for treating HAT since mammals do not have this enzyme.
  • - Researchers synthesized modified versions of AF to better understand how the drug interacts with TAO, discovering that certain chemical groups on AF aid in its effective binding to the enzyme.

Article Abstract

Trypanosoma brucei is a parasite that causes human African trypanosomiasis (HAT). The parasites depend on the cyanide-insensitive trypanosome alternative oxidase (TAO) for their vital aerobic respiration. Ascofuranone (AF), a potent and specific sub-nanomolar inhibitor of the TAO quinol oxidase, is a potential novel drug with selectivity for HAT, because mammalian hosts lack the enzyme. To elucidate not only the inhibition mechanism but also the inhibitor-enzyme interaction, AF derivatives were designed and synthesized, and the structure-activity relationship was evaluated. Here we identified the pharmacophore of AF that interacts with TAO. The detailed inhibitory profiles indicated that the 1-formyl and 6-hydroxyl groups, which might contribute to intramolecular hydrogen bonding and/or serve as hydrogen-bonding donors, were responsible for direct interaction with the enzyme.

Download full-text PDF

Source
http://dx.doi.org/10.1093/jb/mvs135DOI Listing

Publication Analysis

Top Keywords

ascofuranone potent
8
alternative oxidase
8
trypanosoma brucei
8
pharmacophore identification
4
identification ascofuranone
4
potent inhibitor
4
inhibitor cyanide-insensitive
4
cyanide-insensitive alternative
4
oxidase trypanosoma
4
brucei trypanosoma
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!